MedTrace Logo

Biomarkers for Intestinal Permeability in Patients With Constipation

NCT02246647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2019-08-21

Study results available
· View outcomes & findings →

Summary

Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).

Conditions

Interventions

DIAGNOSTIC_TEST

Permeability measurement

Saccharide excretion was compared between IBS-C and healthy volunteers

PROCEDURE

Esophagogastroduodenoscopy

Duodenal biopsies were collected from IBS-C and healthy volunteers

PROCEDURE

Flexible sigmoidoscopy

Colonic biopsies were collected from IBS-C and healthy volunteers

Sponsors & Collaborators

  • Takeda Pharmaceuticals International, Inc.

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Madhusudan Grover, MBBS · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-08
Completion
2016-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02246647 on ClinicalTrials.gov